KURA
Kura Oncology IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$998.71M
P/E Ratio
—
EPS
$-3.35
Beta
0.32
52W High
$12.49
52W Low
$5.45
50-Day MA
$9.02
200-Day MA
$9.17
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
0.00
About Kura Oncology Inc
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops drugs for the treatment of cancer in the United States. The company is headquartered in San Diego, California.
Fundamentals
| Revenue (TTM) | $71.64M |
| Gross Profit (TTM) | $-189.04M |
| EBITDA | $-316.60M |
| Operating Margin | -431.50% |
| Return on Equity | -124.70% |
| Return on Assets | -28.40% |
| Revenue/Share (TTM) | $0.81 |
| Book Value | $1.22 |
| Price-to-Book | 9.26 |
| Price-to-Sales (TTM) | 13.94 |
| EV/Revenue | 6.17 |
| EV/EBITDA | -2.48 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 29.50% |
| Shares Outstanding | $88.77M |
| Float | $70.39M |
| % Insiders | 1.44% |
| % Institutions | 96.33% |
Historical Volatility
HV 10-Day
88.84%
HV 20-Day
68.37%
HV 30-Day
62.98%
HV 60-Day
55.88%
HV Rank
57.5%
Volatility is currently expanding
Analyst Ratings
Consensus ($31.17 target)
2
Strong Buy12
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 5/25/2026